Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone650-251-0005
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$387.29 million
Profitability
Miscellaneous
Employees804
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) posted its quarterly earnings data on Thursday, February, 21st. The medical equipment provider reported ($0.32) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.15. The medical equipment provider had revenue of $107.90 million for the quarter, compared to analyst estimates of $107.39 million. Nevro had a negative return on equity of 20.13% and a negative net margin of 12.70%. The company's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.15) earnings per share. View Nevro's Earnings History.
When is Nevro's next earnings date?
What guidance has Nevro issued on next quarter's earnings?
Nevro issued an update on its FY 2019 earnings guidance on Thursday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400-410 million, compared to the consensus revenue estimate of $419.3 million.
What price target have analysts set for NVRO?
11 equities research analysts have issued 12 month price objectives for Nevro's stock. Their forecasts range from $35.00 to $105.00. On average, they expect Nevro's share price to reach $59.5455 in the next year. This suggests a possible upside of 34.9% from the stock's current price. View Analyst Price Targets for Nevro.
What is the consensus analysts' recommendation for Nevro?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro.
What are Wall Street analysts saying about Nevro stock?
Here are some recent quotes from research analysts about Nevro stock:
- 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (2/27/2019)
- 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)
Has Nevro been receiving favorable news coverage?
Headlines about NVRO stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nevro earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Alkermes (ALKS), Penumbra (PEN), Chemed (CHE), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Healthequity (HQY), Hikma Pharmaceuticals (HKMPF), Patheon (PTHN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Cronos Group (CRON), Novocure (NVCR), ORION OYJ/ADR (ORINY), FibroGen (FGEN) and Medidata Solutions (MDSO).
What other stocks do shareholders of Nevro own?
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Rami Elghandour, Pres, CEO & Director (Age 40)
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
- Mr. Patrick Schmitz, VP of Operations (Age 59)
- Mr. Doug Alleavitch, VP of Quality (Age 58)
- Ms. Juliet Cunningham, VP of Investor Relations
Who are Nevro's major shareholders?
Nevro's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.17%), D. E. Shaw & Co. Inc. (4.36%), Norges Bank (3.13%), Partner Fund Management L.P. (1.84%), Jennison Associates LLC (1.33%) and Northern Trust Corp (1.23%). Company insiders that own Nevro stock include Andrew H Galligan, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which major investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including Zazove Associates LLC, Jennison Associates LLC, Thrivent Financial for Lutherans, Principal Financial Group Inc., MetLife Investment Advisors LLC, Bank of Montreal Can, Northern Trust Corp and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Nevro.
Which major investors are buying Nevro stock?
NVRO stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, D. E. Shaw & Co. Inc., Partner Fund Management L.P., MUFG Securities EMEA plc, MUFG Securities EMEA plc, Canada Pension Plan Investment Board, BlackRock Inc. and SG Americas Securities LLC. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $44.14.
How big of a company is Nevro?
Nevro has a market capitalization of $1.34 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,200,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.
What is Nevro's official website?
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
